Ironwood Pharmaceuticals (IRWD) News Today $3.66 -0.12 (-3.17%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Ozempic, Xtandi among next 15 drugs selected for U.S. price talksJanuary 18 at 1:43 AM | markets.businessinsider.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 3.7% - Here's What HappenedIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 3.7% - Time to Sell?January 17 at 1:14 PM | marketbeat.comOzempic is in the next round of Medicare drug price negotiations. See the full list of 15 medicationsJanuary 17 at 8:07 AM | cnbc.comWhat is Zacks Research's Forecast for IRWD FY2026 Earnings?January 13, 2025 | americanbankingnews.comZacks Research Issues Optimistic Estimate for IRWD EarningsIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, January 8th. Zacks Research analyst R. Department now forecasts that the biotechnoJanuary 13, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 8.7% - Should You Sell?Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 8.7% - Here's What HappenedJanuary 10, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 4.1% - What's Next?Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 4.1% - Here's What HappenedJanuary 2, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Recommendation of "Moderate Buy" by AnalystsIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and tJanuary 1, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Significant Growth in Short InterestIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 12,080,000 shares, an increase of 7.7% from the November 30th total of 11,220,000 shares. Based on an average daily trading volume, of 1,740,000 shares, the short-interest ratio is currently 6.9 days. Currently, 7.8% of the shares of the company are short sold.January 1, 2025 | marketbeat.comJane Street Group LLC Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Jane Street Group LLC raised its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 102.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 323,638 shares of the biotechnologyDecember 29, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 5% - Here's WhyIronwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 5% - What's Next?December 26, 2024 | marketbeat.comState Street Corp Has $40.87 Million Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)State Street Corp raised its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 7.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,919,865 shares of the bioDecember 21, 2024 | marketbeat.comIronwood Pharma (IRWD) Receives a Buy from Craig-HallumDecember 20, 2024 | markets.businessinsider.comIronwood Pharmaceuticals shares surge on competitor's woesDecember 20, 2024 | in.investing.comIronwood jumps after FDA rejects Zealand short bowel syndrome drug applicationDecember 20, 2024 | tipranks.comHere’s Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD)December 20, 2024 | msn.com3 Penny Stocks to Watch for Big Gains in 2025December 19, 2024 | stocknews.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Up 4.6% - What's Next?Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 4.6% - Here's What HappenedDecember 17, 2024 | marketbeat.comZacks Research Has Bearish Estimate for IRWD FY2026 EarningsIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities research analysts at Zacks Research reduced their FY2026 earnings estimates for shares of Ironwood Pharmaceuticals in a research note issued to investors on Tuesday, December 10th. Zacks Research analyst R. Department now forecDecember 13, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 23.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,904,December 11, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by Hodges Capital Management Inc.Hodges Capital Management Inc. trimmed its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 66.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 347,500 shares of the biotechnology company's stock after sellingDecember 9, 2024 | marketbeat.comWeiss Asset Management LP Takes Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Weiss Asset Management LP purchased a new position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 216,707 shares of the biotechnology company's stock, vDecember 9, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Moderate Buy" from AnalystsIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have giveDecember 7, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month Low - Should You Sell?Ironwood Pharmaceuticals (NASDAQ:IRWD) Reaches New 12-Month Low - Here's What HappenedDecember 6, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Bought by Walleye Capital LLCWalleye Capital LLC lifted its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 264.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 280,299 shares of the biotechnology company's stock after buying an additional 20December 6, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC decreased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 48.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 455,477 shareDecember 4, 2024 | marketbeat.comFY2024 Earnings Forecast for IRWD Issued By Zacks ResearchIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a research report issued on Thursday, November 28th. Zacks Research analyst R. Department now antiDecember 2, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Significant Drop in Short InterestIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) was the recipient of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 8,570,000 shares, a drop of 21.8% from the October 31st total of 10,960,000 shares. Based on an average daily volume of 1,630,000 shares, the short-interest ratio is presently 5.3 days. Currently, 5.5% of the shares of the company are sold short.November 30, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 4.4% - What's Next?Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 4.4% - What's Next?November 29, 2024 | marketbeat.comIronwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | finance.yahoo.comPacer Advisors Inc. Grows Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Pacer Advisors Inc. raised its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 26.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,279,822 shares of the biotechnology company's stoNovember 22, 2024 | marketbeat.comAndrew Davis Sells 5,360 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) StockNovember 21, 2024 | insidertrades.comIronwood Pharmaceuticals (IRWD) Stock Declines Despite Industry GainsNovember 20, 2024 | gurufocus.comARMISTICE CAPITAL, LLC Acquires Significant Stake in Ironwood Pharmaceuticals IncNovember 14, 2024 | gurufocus.comGSA Capital Partners LLP Increases Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)GSA Capital Partners LLP lifted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 194.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 351,193 shares of the biotechnology comNovember 14, 2024 | marketbeat.comIronwood Pharmaceuticals to Participate in the Jefferies London Healthcare ConferenceNovember 13, 2024 | businesswire.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three haveNovember 12, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Lowered to "Buy" Rating by StockNews.comStockNews.com lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday.November 12, 2024 | marketbeat.comWhat is Leerink Partnrs' Estimate for IRWD FY2024 Earnings?Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Leerink Partnrs cut their FY2024 earnings estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Thursday, November 7th. Leerink Partnrs analyst F. Khurshid now expects that the biotecNovember 11, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2024 Earnings Call TranscriptNovember 10, 2024 | msn.comRobeco Institutional Asset Management B.V. Increases Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Robeco Institutional Asset Management B.V. grew its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 1,293.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 380,960 shares of the biotechnology company's stock after buying an additNovember 10, 2024 | marketbeat.comPositive Outlook for Ironwood Pharmaceuticals: LINZESS Growth and Apraglutide Potential Drive Buy RatingNovember 8, 2024 | markets.businessinsider.comIronwood Pharmaceuticals Reports Q3 2024 PerformanceNovember 8, 2024 | markets.businessinsider.comIronwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Estimates By $0.07 EPSIronwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). The firm had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. Ironwood Pharmaceuticals had a net margin of 2.30% and a negative return on equity of 6.37%. The company's quarterly revenue was down 19.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.12 EPS.November 8, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 7, 2024 | seekingalpha.comIronwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down - Time to Sell?Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down - Time to Sell?November 7, 2024 | marketbeat.comEarnings Preview: Ironwood PharmaceuticalsNovember 6, 2024 | benzinga.comIronwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Preview: What To ExpectNovember 6, 2024 | finance.yahoo.comCraig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD)November 5, 2024 | markets.businessinsider.com Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Media Mentions By Week IRWD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IRWD News Sentiment▼0.640.46▲Average Medical News Sentiment IRWD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IRWD Articles This Week▼95▲IRWD Articles Average Week Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ligand Pharmaceuticals News Geron News MannKind News Dynavax Technologies News BioCryst Pharmaceuticals News Celldex Therapeutics News Novavax News Myriad Genetics News Innoviva News OPKO Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IRWD) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRWD Stock Alerts